Abstract: The present disclosure is directed to a platform for linking therapeutic compounds to pain phenotypes/conditions and thereby identifying potential novel analgesic therapies. The platform can generate patient selection criteria and/or identify a subset of patients that would be suitable for a clinical trial related to the selected therapeutic compound and the one or more identified pain phenotypes/conditions.

Abstract: This invention provides a method of inhibiting in a mammal neurological damage resulting from impairment of glucose and/or oxygen supply to the brain, which method comprises administering to the mammal prior to the impairment of glucose and/or oxygen supply to the brain an amount of an NR2B subunit selective NMDA antagonist, which amount is effective in inhibiting neurological damage. This invention also provides a method of preventing primary hyperalgesia, secondary hyperalgesia, primary allodynia, secondary allodynia, or other pain caused by central sensitization, in a mammal, which method comprises administering to the mammal, prior to affliction with said pain, an amount of an NR2B subunit selective NMDA antagonist, which amount is effective in preventing said pain.